Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 5,942 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus
Interventions
JTT-252 or Placebo, JTT-252
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Austin, Texas
Conditions
Myelodysplastic Syndrome
Interventions
Clofarabine
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Type II Diabetes Mellitus
Interventions
AZD1656
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
San Diego, California • San Antonio, Texas
Conditions
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
219
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more
Conditions
Xerostomia, Halitosis
Interventions
Crest Daily Whitening Serum
Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Herpes Simplex
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 12 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 8 more
Conditions
Southern Tick-Associated Rash Illness
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
AMS, Acute Mountain Sickness
Interventions
Immediate descent from altitude., Diphenhydramine, Prochlorperazine 10 mg
Other · Drug
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Corpus Christi, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Variation in Gingival Inflammatory Responses

NCT05968742
Conditions
Gingivitis
Interventions
Abstinence of oral hygiene on select teeth
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 35 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Carcinoma, Renal Cell
Interventions
Topotecan, Radiation therapy
Drug · Radiation
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma, Oral Cavity Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Carcinoma, Recurrent Oral Cavity Carcinoma, Recurrent Oropharyngeal Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Celecoxib, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
LAD1
Interventions
Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Conditions
Head and Neck Cancer
Interventions
methotrexate, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
19
States / cities
Atlanta, Georgia • Decatur, Georgia • Chicago, Illinois + 13 more
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
Vitamin D
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Not applicable Interventional Accepts healthy volunteers

Oral Hygiene Intervention Pilot Study

NCT02668809
Conditions
Dental Caries, Gingivitis
Interventions
oral health assessment, Questionnaires, Clinical Exam, Microbiological sampling, Monitoring Adherence, Varnish application, Consent, Educational Program
Other
Lead sponsor
Leonardo Marchini
Other
Eligibility
21 Years to 120 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Not applicable Interventional Accepts healthy volunteers

Turmeric and Turmeric-containing Tablets and Sebum Production

NCT03065504
Conditions
Skin Inflammation
Interventions
Turmeric, Turmeric-containing combination tablet, Placebo tablets
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Conditions
Diabetic Foot Ulcers
Interventions
ofloxacin, MSI-78
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Healthy Participants
Interventions
Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Conditions
Periodontal Diseases
Interventions
mechanical debridement, adjunctive aPDT, sham aPDT
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myeloid Leukemia
Interventions
Oral Azacitidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
Cytology specimen, Laboratory biomarker analysis
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Not yet recruiting No phase listed Observational

Penn SICCA Follow-up Study

NCT05056012
Conditions
Dry Eye, Sjogren's Syndrome
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alveolar Bone Loss
Interventions
50% cortical/50% cancellous FDBA, 100% cortical FDBA, 100% cancellous FDBA
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Antonio, Texas